Companies › Windtree Therapeutics
Windtree Therapeutics: clinical trials, targets and expected readouts
1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular.
Open in Phaseline: competitors, likelihood bands and readouts Company report
Programs Drug Target Highest phase Conditions Next expected readout Istaroxime Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator
Na+/K+-ATPase , ATP1B2 , ATP1B1 , ATP1B3 , FXYD2 Phase 1 Cardiogenic Shock –
Trials Registry id Drug Phase Conditions Area Expected readout NCT05975021 Istaroxime Phase 1 Cardiogenic Shock Cardiovascular Jul 2025
From the company's SEC filings Cash of $0m on 2025-09-30; operating cash outflow about $15m a year; runway about 0 months at that burn, to Oct 2025
Agreements filed with the SEC (item 1.01), last two years 2026-07-22 · acquisition with Seismic Pharmaceutical · This Asset Purchase Agreement (the “ Agreement ”) is dated and effective as of December 16, 2025, by and betwe 2025-05-01 · collaboration with Way Maker Growth Fund, LLC · Assignment of Purchase Agreement On April 19, 2025, WINT Real Estate, LLC (“ WINT LLC ”), a wholly owned subsi 2025-04-10 · acquisition · Convertible Promissory Note On April 4, 2025, the Company agreed to issue and sell to two institutional invest 2025-03-24 · licence with Evofem Biosciences · License and Supply Agreement with Evofem Biosciences, Inc. On March 20, 2025, Windtree Therapeutics, Inc. (the
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.
Built from ClinicalTrials.gov, CTIS, FDA, PubMed and OpenAlex, read every week; this page from the landscape of 2026-11-09. Phaseline reads registries; it is not investment or medical advice. Method and sources · Privacy · Contact